Salix Pharmaceuticals continues to roll up partners in a bid to broaden its reach. Its latest deal not only beefs up its own portfolio, but gives Dova Pharmaceuticals a co-promotional boost for its chronic liver disease drug Doptelet, which just won FDA approval.
